SAN DIEGO, Calif., June 28 /PRNewswire/ -- Genoptix, Inc., a CLIA and CAP certified clinical laboratory, today announced it will provide expertise in flow cytometry testing to Biogen Idec and will collaborate with the company in assay development to support upcoming clinical trials.
Genoptix is well known for its focus on providing high quality and personalized clinical esoteric services to hematologists/oncologists, which aid in the evaluation and management of hematomalignancies. In addition, Genoptix supports clinical trails of companies with valuable potential therapeutics in the hematomalignancy area.
"This opportunity allows both Genoptix and Biogen Idec to work to their respective strengths and improve the development of new drugs," said Tina Nova, Ph.D., Genoptix President and CEO. "We feel strongly that our organization is well poised to provide the type of flexibility, innovative thinking and collaborative approach that will help create value for both companies and benefit physicians and patients. Our medical and laboratory team has tremendous experience across varied laboratory platforms, whether that is 6 color flow, quantitative PCR or cellular assays, but the main focus is always on quality and integration of services."
About Genoptix
Genoptix, Inc. (www.genoptix.com), headquartered in Carlsbad, CA, provides Personalized Medicine Services to hematologists and oncologists that combine proprietary and exclusive tests with advanced clinical techniques for comprehensive evaluation of individual patients. To inquire about partnerships, contact Mike Nerenberg, M.D. at (760) 268-6200 or mnerenberg@genoptix.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Actual results may differ materially from those projected. Genoptix disclaims, however, any intent or obligations to update these forward-looking statements.
Genoptix, Inc.CONTACT: Tina S. Nova, Ph.D, President and Chief Executive Officer ofGenoptix, Inc., +1-760-268-6200, info@genoptix.com; or Kathy W. Sweeney ofMentus, +1-858-455-5500, ext. 230, kwitz@mentus.com, for Genoptix, Inc.
Web site: http://www.genoptix.com//
